Psych Vivas · Psychopharmacology — antipsychotics
Antipsychotics — cross-table viva
Fellowship viva on receptor maps, landmark trials, monitoring, LAI, clozapine threshold, and emergency adverse effects.
On this page
Study tools
Target exams
FRANZCPMRCPsychABPNMD-DNB
Prompt
Examiner places a blank table: pathways vs adverse effects, then asks you to place CATIE, CUtLASS, EUFEST, Leucht NMA, TRRIP and InterSePT in one minute each.
Station structure
Time: 8–10 minutes. Depth: consultant teaching registrar. Expect pathway maps, trial one-liners, and safe prescribing without marketing slogans.[3]
References5ShowHide
- [1]Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med, 2005.PMID 16172203
- [2]Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) Arch Gen Psychiatry, 2006.PMID 17015810
- [3]Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis Lancet, 2013.PMID 23810019
- [4]Howes OD, McCutcheon R, Agid O, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology Am J Psychiatry, 2017.PMID 27919182
- [5]Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT) Arch Gen Psychiatry, 2003.PMID 12511175